Pharmabiz12h
US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma
US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma: London, UK Wednesday, January 8, 2025, 10:00 ...
Pharmabiz13h
MTaI to host MedTekon 2025 in New Delhi on January 30
Our Bureau, New Delhi Wednesday, January 8, 2025, 09:00 Hrs [IST] Medical Technology Association of India (MTaI), which repr ...
Pharmabiz14h
Govt yet to notify rules for compounding offences as per amendments introduced through Jan Vishwas Act
Govt yet to notify rules for compounding offences as per amendments introduced through Jan Vishwas Act: Shardul Nautiyal, Mumbai Wednesday, January 8, 2025, 08:00 Hrs [IST] Despit ...
Pharmabiz11h
US FDA issues comprehensive draft guidance for developers of AI -enabled medical devices
US FDA issues comprehensive draft guidance for developers of AI -enabled medical devices: Maryland Wednesday, January 8, 2025, 11:00 Hrs [IST] The US Food and Drug Administration ...
Pharmabiz14h
Govt must adopt a pragmatic approach on revised Schedule M similar to US FDA compliance: Manoj Palrecha
Govt must adopt a pragmatic approach on revised Schedule M similar to US FDA compliance: Manoj Palrecha: Nandita Vijayasimha, Bengaluru Wednesday, January 8, 2025, 08:00 Hrs [IST] ...
Pharmabiz14h
TN DCA gearing up for inspection of pharma units to ensure compliance with revised Schedule M
Peethaambaran Kunnathoor, Chennai Wednesday, January 8, 2025, 08:00 Hrs [IST] ...
Pharmabiz14h
Indian health sector navigating complexities of M&As: Harsh Vaish
Harsh Vaish: Nandita Vijayasimha, Bengaluru Wednesday, January 8, 2025, 08:00 Hrs [IST] Mergers and Acquisitions (M&As) have ...
Pharmabiz14h
MAKE HOSPITALS A SAFER PLACE
Of course, safety and security in hospitals have been a matter of great concern in the country. There have been reports of intermittent violence against the medical fraternity by the relatives of the ...
Pharmabiz1d
Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary
Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary: Our Bureau, Mumbai Tuesday, January 7, 2025, 17:15 Hrs [IST] Zydus L ...
Pharmabiz1d
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection
Acurx Pharma receives positive regulatory guidance from EMA for ibezapolstat phase 3 programme for C. difficile infection: Staten Island, New York Tuesday, January 7, 2025, 18:00 ...
Pharmabiz1d
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...
Pharmabiz1d
SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative Gamma Delta T-cell cancer therapy in India
Our Bureau, Mumbai Tuesday, January 7, 2025, 16:45 Hrs [IST] ...